|
Summaries of Product Characteristics (SPC) for Human medicinal products
The summaries of product characteristics (SPC) contain the information relevant to the use of the medicinal products and of importance to health care professionals. The SPCs are published in Finnish; the use of Finnish key words in the search fields is therefore recommended.
Some of the medicinal products contain a condition relevant to the prescribing of the product and not always found in the SPC. The conditions for prescribing and the products covered by this condition are found in the FimeaWeb search.
The SPCs processed as part of the EU centralised marketing authorisation procedure are published by the European Medicines Agency, EMA. Fimea's service contains links to the documents on medicinal products (EPAR PI) on the EMA website. Drugs belonging to the centralised authorisation procedure can be searched in Fimea's service by using an alphabetical list or by entering the product name or ATC code.
The material being published is not necessarily complete or up-to-date due to the technical quality of files submitted to the Finnish Medicines Agency Fimea or earlier to the National Agency for Medicines and the delays in delivery. For this reason, Fimea cannot guarantee that the document on the Internet fully complies with the summary of product characteristics and package leaflet officially approved by a desicion for a marketing authorisation. Only the hard copies of the SPCs and the PLs, which are in accordance with the marketing authorisation, are conclusive.
Summaries of Product Characteristics 301 - 330 of 460 |
|
|
Package leaflet | Status for supply | Name of the medicinal product |
PL
|
Resepti
|
Apremilast Krka 10 mg-20 mg-30 mg, 30 mg tabletti, kalvopäällysteinen SPC 2024-05-03
|
PL
|
Resepti
|
Apremilast ratiopharm 30 mg tabletti, kalvopäällysteinen SPC 2024-06-20
|
PL
|
Resepti
|
Apremilast Sandoz 10 mg-20 mg-30 mg ja 30 mg tabletti, kalvopäällysteinen SPC 2024-05-14
|
PL
|
Resepti
|
Aprepitant Stada 80 mg, 125 mg, 125 mg + 80 mg kapseli, kova SPC 2020-02-18
|
|
|
European Medicines Agency's website: Apretude - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Aprokam 50 mg injektiokuiva-aine, liuosta varten SPC 2021-10-25
|
|
|
European Medicines Agency's website: Aprovel - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Aptivus - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Apurin Sandoz 100 mg, 300 mg tabletti SPC 2021-12-10
|
PL
|
Resepti
|
Apydan 300 mg tabletti SPC 2022-07-06
|
PL
|
Resepti
|
Apydan 600 mg tabletti SPC 2022-07-06
|
PL
|
Resepti
|
Aqua Sterilisata Braun infuusioneste, liuos SPC 2020-01-16
|
PL
|
Resepti
|
Aqua Sterilisata Braun liuotin parenteraaliseen käyttöön SPC 2020-01-03
|
PL
|
Resepti
|
Aqua Sterilisata Fresenius Kabi injektioneste, liuos, SPC 2020-04-30
|
|
|
European Medicines Agency's website: AQUIPTA - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Aranesp - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Arava - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Arcoxia 30 mg, 60 mg, 90 mg, 120 mg tabletti, kalvopäällysteinen SPC 2023-10-31
|
PL
|
Resepti
|
Ardinex 200 mg-30 mg tabletti SPC 2023-01-05
|
PL
|
Resepti
|
Ardinex 400 mg-30 mg tabletti SPC 2023-04-18
|
|
|
European Medicines Agency's website: Arexvy - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Aridol inhalaatiojauhe, kapseli, kova SPC 2019-03-01
|
|
|
European Medicines Agency's website: ARIKAYCE liposomal - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Arilin 250mg tabletti, kalvopäällysteinen SPC 2024-04-30
|
PL
|
Resepti
|
Arilin 500 mg tabletti, kalvopäällysteinen SPC 2024-04-30
|
PL
|
Resepti
|
Arimidex 1 mg tabletti, kalvopäällysteinen SPC 2021-11-04
|
PL
|
Resepti
|
Aripiprazol Krka 5 mg, 10 mg, 15 mg, 30 mg tabletti SPC 2023-02-22
|
PL
|
Resepti
|
Aripiprazol Stada 1 mg-ml oraaliliuos SPC 2023-04-25
|
PL
|
Resepti
|
Aripiprazol Stada 10 mg, 15 mg tabletti, suussa hajoava SPC 2022-08-29
|
PL
|
Resepti
|
Aripiprazol Stada 5 mg, 10 mg, 15 mg, 30 mg tabletti SPC 2022-08-23
|
|
| |